Abstract:Butyrylcholinesterase (BChE) has been considered as a potential therapeutic target for Alzheimer's disease (AD) because of its compensation capacity to hydrolyze acetylcholine (ACh) and its close association with Aβ deposit. Here, we identified S06-1011 (hBChE IC50 = 16 nM) and S06-1031 (hBChE IC50 = 25 nM) as highly effective and selective BChE inhibitors, which were proved to be safe and long-acting. Candidate compounds exhibited neuroprotective effects and the ability to improve cognition in scopolamine- and Aβ1–42 peptide-induced cognitive deficit models. The best candidate S06-1011 increased the level of ghrelin, a substrate of BChE, which can function as improving the mental mood appetite. The weight gain of the S06-1011-treated group remarkably increased. Hence, BChE inhibition not only plays a protective role against dementia but also exerts a great effect on treating and nursing care.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00167?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00167</a>.Molecular dynamics—8012-9656 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_001.pdb">PDB</a>)Molecular dynamics—S06-1002 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_002.pdb">PDB</a>)Molecular dynamics—S06-1011 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_003.pdb">PDB</a>)Molecular dynamics—S06-1014 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_004.pdb">PDB</a>)Molecular string formulas (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_005.csv">CSV</a>)Compound characterization; inhibitory rates on eeAChE and on eqBChE of partial compounds; molecular docking modes of S06-1002, S06-1011, and S06-1014; molecular dynamic simulation results of S06-1001, S06-1002, S06-1011, and S06-1014; chromatographic and mass spectrometric identification information for S06-1011; standard curves for pharmacokinetics and PAMPA study; quantization of ROS production; protocol for the in vivo experiments (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00167/suppl_file/jm1c00167_si_006.pdf">PDF</a>)This article has not yet been cited by other publications.

A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement

Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection

Discovery, Structure-Based Modification, In Vitro , In Vivo , and In Silico Exploration of m -Sulfamoyl Benzoamide Derivatives as Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer’s Disease

Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening

Discovery of New Selective Butyrylcholinesterase (BChE) Inhibitors with Anti-Aβ Aggregation Activity: Structure-Based Virtual Screening, Hit Optimization and Biological Evaluation

Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor

Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

N-Benzyl Benzamide Derivatives As Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer’s Disease

Design, synthesis and biological evaluation of novel pyrazolone derivatives as selective butyrylcholinesterase inhibitors with antioxidant activity against Alzheimer's disease

N -Benzyl Benzamide Derivatives as Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer's Disease

Development of the “hidden” multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer's disease

Synthesis and biological evaluation of substituted acetamide derivatives as potential butyrylcholinestrase inhibitors

Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer’s Disease Mouse Model

Searching for the Multi-Target-Directed Ligands Against Alzheimer'S Disease: Discovery of Quinoxaline-Based Hybrid Compounds with Ache, H3r and Bace 1 Inhibitory Activities

Design, Synthesis, and Bioevaluation of Benzamides: Novel Acetylcholinesterase Inhibitors with Multi-Functions on Butylcholinesterase, Aβ Aggregation, and Β-Secretase.

New insights into butyrylcholinesterase: Pharmaceutical applications, selective inhibitors and multitarget-directed ligands

Dual-target-directed 1,3-Diphenylurea Derivatives: BACE 1 Inhibitor and Metal Chelator Against Alzheimer’s Disease

Novel anti-neuroinflammatory pyranone-carbamate derivatives as selective butyrylcholinesterase inhibitors for treating Alzheimer's disease

Discovery of a Selective 6-Hydroxy-1, 4-Diazepan-2-one Containing Butyrylcholinesterase Inhibitor by Virtual Screening and MM-GBSA Rescoring

Discovery of new multifunctional selective acetylcholinesterase inhibitors: structure-based virtual screening and biological evaluation

A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase